<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vedolizumab for induction and maintenance of remission in ulcerative colitis - Bickston, SJ - 2014 | Cochrane Library</title> <meta content="Vedolizumab for induction and maintenance of remission in ulcerative colitis - Bickston, SJ - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007571.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vedolizumab for induction and maintenance of remission in ulcerative colitis - Bickston, SJ - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007571.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007571.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Vedolizumab for induction and maintenance of remission in ulcerative colitis" name="citation_title"/> <meta content="Stephen J Bickston" name="citation_author"/> <meta content="Center for Inflammatory Bowel Diseases" name="citation_author_institution"/> <meta content="sbickston@mcvh-vcu.edu" name="citation_author_email"/> <meta content="Brian W Behm" name="citation_author"/> <meta content="University of Virginia Health Systems" name="citation_author_institution"/> <meta content="David J Tsoulis" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Jianfeng Cheng" name="citation_author"/> <meta content="University of North Carolina Charlotte Campus" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Reena Khanna" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD007571.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/08/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007571.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007571.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007571.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; Colitis, Ulcerative [prevention &amp; control, *therapy]; Induction Chemotherapy [*methods]; Maintenance Chemotherapy [*methods]; Randomized Controlled Trials as Topic; Secondary Prevention" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007571.pub2&amp;doi=10.1002/14651858.CD007571.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tlnpj831";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007571\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007571\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007571.pub2",title:"Vedolizumab for induction and maintenance of remission in ulcerative colitis",firstPublishedDate:"Aug 8, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007571.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007571.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007571.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007571.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007571.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007571.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007571.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007571.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007571.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007571.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3279 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007571.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0036"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0029"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-sec-0035"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/appendices#CD007571-sec-0041"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/table_n/CD007571StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/table_n/CD007571StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vedolizumab for induction and maintenance of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Stephen J Bickston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0003">Brian W Behm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0004">David J Tsoulis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0005">Jianfeng Cheng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0006">John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0007">Reena Khanna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information#CD007571-cr-0008">Brian G Feagan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information/en#CD007571-sec-0044">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 August 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007571.pub2">https://doi.org/10.1002/14651858.CD007571.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007571-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007571-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007571-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007571-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007571-abs-0001" lang="en"> <section id="CD007571-sec-0001"> <h3 class="title" id="CD007571-sec-0001">Background</h3> <p>Cellular adhesion molecules play an important role in the pathogenesis of ulcerative colitis, making selective blockade of these molecules a promising therapeutic strategy. Vedolizumab, a recombinant humanized IgG1 monoclonal antibody, inhibits adhesion and migration of leukocytes into the gastrointestinal tract by binding the alpha4beta7 integrin. Animal studies have suggested that vedolizumab may be a useful therapy for ulcerative colitis. This updated systematic review summarizes the current evidence on the use of vedolizumab for induction and maintenance of remission in ulcerative colitis. </p> </section> <section id="CD007571-sec-0002"> <h3 class="title" id="CD007571-sec-0002">Objectives</h3> <p>The primary objectives were to determine the efficacy and safety of vedolizumab used for induction and maintenance of remission in ulcerative colitis. </p> </section> <section id="CD007571-sec-0003"> <h3 class="title" id="CD007571-sec-0003">Search methods</h3> <p>A computer‐assisted search for relevant studies (inception to 15 June 2014) was performed using PubMed, MEDLINE, EMBASE and CENTRAL. References from published articles and conference proceedings were searched to identify additional citations. </p> </section> <section id="CD007571-sec-0004"> <h3 class="title" id="CD007571-sec-0004">Selection criteria</h3> <p>Randomized controlled trials comparing vedolizumab to placebo or a control therapy for induction or maintenance of remission in ulcerative colitis were included. </p> </section> <section id="CD007571-sec-0005"> <h3 class="title" id="CD007571-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed the risk of bias for each trial. The primary outcomes were failure to induce clinical remission and relapse. Secondary outcomes included failure to induce a clinical response, failure to induce endoscopic remission, failure to induce an endoscopic response, quality of life, adverse events, serious adverse events and withdrawal due to adverse events. We calculated the relative risk (RR) and 95% confidence intervals (CI) for each outcome. Data were analyzed on an intention‐to‐treat basis. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. </p> </section> <section id="CD007571-sec-0006"> <h3 class="title" id="CD007571-sec-0006">Main results</h3> <p>Four studies (606 patients) were included. All of the studies were rated as having a low risk of bias. Pooled analyses revealed that vedolizumab was significantly superior to placebo for induction of remission, clinical response, and endoscopic remission and prevention of relapse. After 4 to 6 weeks of therapy 77% (293/382) of vedolizumab patients failed to enter clinical remission compared to 92% (205/224) of placebo patients (RR 0.86, 95% CI 0.80 to 0.91; 4 studies 606 patients). After 6 weeks of therapy 48% of vedolizumab patients failed to have a clinical response compared to 72% of placebo patients (RR 0.68, 95% CI 0.59 to 0.78; 3 studies 601 patients). After 4 to 6 weeks of therapy 68% of vedolizumab patients failed to enter endoscopic remission compared to 81% of placebo patients (RR 0.82, 95% CI 0.75 to 0.91; 3 studies, b583 patients). After 52 weeks of therapy, 54% of vedolizumab patients had a clinical relapse compared to 84% of placebo patients (RR 0.67, 95% CI 0.59 to 0.77; 1 study, 373 patients). One small study (28 patients) found no statistically significant difference in endoscopic response (RR 1.00, 95% CI 0.62 to 1.61). GRADE analyses indicated that the overall quality of the evidence for the primary outcomes was high for induction of remission and moderate for relapse (due to sparse data 246 events). There was no statistically significant difference between vedolizumab and placebo in terms of the risk of any adverse event (RR 0.99, 95% CI 0.93 to 1.07), or serious adverse events (RR 1.01, 95% CI 0.72 to 1.42). There was a statistically significant difference in withdrawals due to adverse events. Six per cent of vedolizumab patients withdrew due to an adverse event compared to 11% of placebo patients (RR 0.55, 95% CI 0.35 to 0.87; 2 studies, 941 patients). Adverse events commonly reported across the studies included: worsening ulcerative colitis, headache, nasopharyngitis, upper respiratory tract infection, nausea, and abdominal pain. </p> </section> <section id="CD007571-sec-0007"> <h3 class="title" id="CD007571-sec-0007">Authors' conclusions</h3> <p>Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative colitis. Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. Adverse events appear to be similar to placebo. Future trials are needed to define the optimal dose, frequency of administration and long‐term efficacy and safety of vedolizumab used for induction and maintenance therapy of ulcerative colitis. Vedolizumab should be compared to other currently approved therapies for ulcerative colitis in these trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007571-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007571-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007571-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007571-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007571-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007571-abs-0003" lang="en"> <h3>Vedolizumab for the treatment of active and inactive ulcerative colitis</h3> <p>Ulcerative colitis is a chronic inflammatory disease of the colon. Vedolizumab (formerly known as MLN‐02) is a synthetic antibody that blocks the adhesion and migration of white blood cells into the gut, reducing intestinal inflammation. This medication is given to patients intravenously. Four studies including 606 patients were included in this review. Pooled analysis of these trials revealed vedolizumab is significantly more effective than placebo (sham infusion) for inducing clinical remission and response (improvement of symptoms), as well as endoscopic remission (healing of inflamed mucosa in the colon) in patients with moderate to severely active ulcerative colitis. Evidence from one study suggests that vedolizumab is superior to placebo for preventing relapse (recurrence of active disease) in patients with ulcerative colitis in remission. Patients receiving vedolizumab were no more likely than placebo patients to experience side effects or serious side effects. Commonly reported side effects included: worsening ulcerative colitis, headache, nasopharyngitis (inflammation of nose and throat), upper respiratory tract infection, nausea, and abdominal pain. Further research is needed in order to define the optimal dose, frequency of drug administration and the long‐term effectiveness and safety of vedolizumab used for induction and maintenance of remission in ulcerative colitis. Vedolizumab should be compared to other currently approved therapies of ulcerative colitis in these studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007571-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007571-sec-0036"></div> <h3 class="title" id="CD007571-sec-0037">Implications for practice</h3> <section id="CD007571-sec-0037"> <p>There is now moderate to high quality evidence from four randomized controlled trials that vedolizumab is more effective than placebo for induction of clinical remission and response and endoscopic remission in patients with moderately to severely active ulcerative colitis. Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. Various doses of vedolizumab were used in these trials. <a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a> observed the greatest rate of endoscopic response in those receiving 0.5 mg/kg. Similarly, <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> observed the greatest decrease in ulcerative colitis clinical score using the same dose. <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> reported the greatest effect for a 6 mg/kg dose at a similar time point. The <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study used a 300 mg dose. </p> </section> <h3 class="title" id="CD007571-sec-0038">Implications for research</h3> <section id="CD007571-sec-0038"> <p>Biologic therapies now play a central role in the management of inflammatory bowel diseases. The approval of natalizumab for Crohn's disease can be expected to encourage further development of therapies that target adhesion and integrin mechanisms. The data for vedolizumab are positive and should encourage further investigation. Data from larger trials or databases are needed to confirm the long‐term safety and efficacy of vedolizumab as induction and maintenance therapy for patients with ulcerative colitis. The optimal dose and frequency of administration of vedolizumab needs to be further defined. Ideally, future research should also include active comparators. These trials should include additional patient populations, including patients who are dependent on or refractory to corticosteroids. </p> <p>In addition, although immunogenicity seems to be decreased with the use of the CHO‐derived vedolizumab, further investigations into whether immunogenicity can be further lowered by dosing strategies or by the use of concomitant immunosuppressives should be explored. Furthermore, the efficacy of combination therapy (i.e. vedolizumab and immunosuppressives) will need to be assessed in future trials. Given that immunosuppressive use has been identified as a risk factor for PML, it seems prudent to use the risk factor stratification outlined by <a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a> in the design of such studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007571-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007571-sec-0015"></div> <div class="table" id="CD007571-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vedolizumab versus placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Vedolizumab versus placebo for induction of remission in ulcerative colitis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with moderately to severely active ulcerative colitis<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Vedolizumab versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vedolizumab versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>915 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>787 per 1000</b> <br/> (732 to 833) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.80 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>720 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>490 per 1000</b> <br/> (425 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b> <br/> (0.59 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>601<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>809 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>663 per 1000</b> <br/> (607 to 736) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b> <br/> (0.75 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>841 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>563 per 1000</b> <br/> (496 to 648) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b> <br/> (0.59 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>802 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>465 per 1000</b> <br/> (393 to 545) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b> <br/> (0.49 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>799 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>791 per 1000</b> <br/> (743 to 855) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> <br/> (0.93 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>941<br/> (2 studies)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>121 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>122 per 1000</b> <br/> (87 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.72 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1122<br/> (3 studies)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Sparse data (342 events).<br/> <sup>3</sup> Sparse data (246 events).<br/> <sup>4</sup> Sparse data (215 events).<br/> <sup>5</sup> Includes full safety population from <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study (induction and maintenance phase).<br/> <sup>6</sup> Sparse data (136 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007571-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007571-sec-0016"></div> <p>Ulcerative colitis is a chronic idiopathic inflammatory disease of the colon that is characterized by abdominal pain and bloody diarrhea. Conventional treatments for patients with active disease may include 5‐aminosalicylates, corticosteroids, and azathioprine or 6‐mercaptopurine. Infliximab, a neutralizing mouse or human immunoglobulin (Ig)G<sub>1</sub> chimeric anti‐human tumour necrosis factor monoclonal antibody, may be effective for patients with moderate to severely active disease who have an inadequate response to conventional therapy (<a href="./references#CD007571-bbs2-0012" title="LawsonMM , ThomasAG , AkobengAK . Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005112.pub2] ">Akobeng 2006</a>; <a href="./references#CD007571-bbs2-0020" title="KornbluthA , SacharD , The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology2010;105:501–23. ">Kornbluth 2010</a>). The calcineurin inhibitor cyclosporine may be effective for patients with severe steroid‐refractory disease (<a href="./references#CD007571-bbs2-0026" title="ShiboletO , RegushevskayaE , BrezisM , Soares‐WeiserK . Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD004277.pub2] ">Shibolet 2005</a>). Despite currently available treatment options, some patients will require colectomy because of intolerance or lack of response to medical therapy. Identification of other treatment strategies for ulcerative colitis is thus an important area of research. </p> <p>Cellular adhesion molecules play an important role in the pathogenesis of intestinal inflammation, and have been studied as potential therapeutic targets in inflammatory bowel disease. One potential target is the alpha4beta7 integrin, a molecule found on circulating T lymphocytes that is involved in recruitment of leukocytes to the gastrointestinal tract (<a href="./references#CD007571-bbs2-0015" title="ErleDJ , BriskinMJ , ButcherEC , Garcia‐PardoA , LazarovitsAI , TidswellM . Expression and function of the MAdCAM‐1 receptor, integrin alpha 4 beta 7, on human leukocytes. Journal of Immunology1994;153(2):517‐28. ">Erle 1994</a>). The major ligand of alpha4beta7, mucosal adressin‐cell adhesion molecule‐1 (MAdCAM‐1), is selectively expressed on the endothelium of the intestinal vasculature and is present in increased concentrations in areas of intestinal inflammation. Studies evaluating natalizumab, a humanized IgG4 monoclonal antibody that leads to inhibition of the alpha4 integrin, found natalizumab to be effective for the induction and maintenance of remission of Crohn's disease (<a href="./references#CD007571-bbs2-0023" title="SandbornWJ , ColombelJF , EnnsR , FeaganBG , HanauerSB , LawranceIC , et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med2005;353(18):1912‐25. ">Sandborn 2005</a>; <a href="./references#CD007571-bbs2-0022" title="MacDonaldJK , McDonaldJWD . Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006097.pub2] ">MacDonald 2007</a>; <a href="./references#CD007571-bbs2-0027" title="TarganSR , FeaganBG , FedorakRN , LashnerBA , PanaccioneR , PresentDH , et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology2007;132(5):1672‐83. ">Targan 2007</a>). However, reports of progressive multifocal leukoencephalopathy (PML) in patients taking natalizumab as part of multi‐drug therapy have raised concerns regarding the safety of broad inhibition of the alpha4 integrin (<a href="./references#CD007571-bbs2-0028" title="YousryTA , MajorEO , RyschkewitschC , FahleG , FischerS , HouJ , et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med2006;354(9):924‐33. ">Yousry 2006</a>; <a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a>). Therapies directed at alpha4beta7 integrin may be associated with a more selective inhibition of T cell homing, possibly resulting in less impairment of systemic immunity while reducing intestinal inflammation. </p> <p>Vedolizumab is a humanized monoclonal IgG1 antibody specific for the alpha4beta7 integrin that does not cross‐react with the alpha4 monomer. Treatment with vedolizumab results in reduced intestinal inflammation in a cotton‐top tamarin model of colitis (<a href="./references#CD007571-bbs2-0018" title="HesterbergPE , Winsor‐HinesD , BriskinMJ , Soler‐FerranD , MerrillC , MackayCR , et al. Rapid resolution of chronic colitis in the cotton‐top tamarin with an antibody to a gut‐homing integrin alpha 4 beta 7. Gastroenterology1996;111(5):1373‐80. ">Hesterberg 1996</a>). Further study in healthy cynomolgus monkeys showed that vedolizumab has selective activity in its effects on gastrointestinal tissue. In the gut it brought changes in leukocytes and β lymphocytes; this was not seen in other organs (<a href="./references#CD007571-bbs2-0016" title="FedykER , WyantT , YangLL , CsizmadiaV , BurkeK , YangH , et al. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates. Inflammatory Bowel Diseases2012;18(11):2107‐19. ">Fedyk 2012</a>). Data from earlier dose‐ranging studies in humans suggested vedolizumab is safe and possibly effective in patients with ulcerative colitis (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>). This systematic review and meta‐analysis summarizes the current evidence regarding the use of vedolizumab for the induction of remission in ulcerative colitis. This systematic review is an update of a previously published Cochrane review (<a href="./references#CD007571-bbs2-0029" title="BehmBW , BickstonSJ . Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD007571] ">Behm 2009</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007571-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007571-sec-0017"></div> <p>The primary objective was to determine the efficacy and safety of vedolizumab used for induction and maintenance of remission in ulcerative colitis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007571-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007571-sec-0018"></div> <section id="CD007571-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007571-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials were considered for inclusion.</p> </section> <section id="CD007571-sec-0021"> <h4 class="title">Types of participants</h4> <p>Adult patients (&gt;18 years of age) with active or quiescent ulcerative colitis as defined by conventional clinical, histological or endoscopic criteria were considered for inclusion. </p> </section> <section id="CD007571-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Trials where vedolizumab was compared to placebo or a control medication were considered for inclusion. </p> </section> <section id="CD007571-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>The primary outcome measures were the proportion of patients who failed to achieve clinical remission and the proportion of patients who relapsed as defined by the included studies. Secondary outcomes included the proportion of patients who failed to have a clinical response, failure to enter endoscopic remission, failure to have an endoscopic response, endoscopic relapse, disease‐specific quality of life, adverse events, withdrawal due to adverse events and serious adverse events. </p> </section> </section> <section id="CD007571-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>A computer‐assisted search of PubMed (1966 to 15 June 2014), MEDLINE (1966 to 15 June 2014), EMBASE (1980 to 15 June 2014), and CENTRAL (Cochrane Library, Issue 6, 2014) was performed. The search strategies are reported in <a href="./appendices#CD007571-sec-0042">Appendix 1</a>. </p> <p>Furthermore, two authors (DJT and JKM) hand‐searched the articles cited in each full text publication obtained. Manual searches to identify key conference abstracts from 1999 onwards were performed [i.e. Gastroenterology (American Gastroenterological Association); Gut (British Society of Gastroenterology); American Journal of Gastroenterology (American College of Gastroenterology)]. References from published articles were searched to identify additional citations. Unpublished data from on‐going trials were identified by correspondence with authors and experts in the field. </p> </section> <section id="CD007571-sec-0025"> <h3 class="title" id="CD007571-sec-0025">Data collection and analysis</h3> <section id="CD007571-sec-0026"> <h4 class="title">Selection criteria</h4> <p>Publications identified by the search strategy were independently assessed by two authors (DJT and JKM). Relevant studies were selected according to the inclusion criteria. </p> </section> <section id="CD007571-sec-0027"> <h4 class="title">Data collection and analysis</h4> <p>Both authors independently reviewed the full texts independently and assessed the eligibility of the trials based on the inclusion criteria above. The methodological quality of the included studies was assessed using the Cochrane risk of bias tool (<a href="./references#CD007571-bbs2-0019" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This tool involves a number of factors: </p> <p> <ol id="CD007571-list-0001"> <li> <p>Sequence generation (i.e. method of randomisation);</p> </li> <li> <p>Allocation sequence concealment;</p> </li> <li> <p>Appropriate blinding;</p> </li> <li> <p>Incomplete outcome reporting (i.e. the investigators had determined methods of dealing with attrition) </p> </li> <li> <p>Selective outcome reporting (i.e. the investigators reported all <i>a priori</i> outcomes) </p> </li> <li> <p>Other sources of bias (i.e. anything else in the study that could have increased the risk of bias) </p> </li> </ol> </p> <p>The studies were judged to be of high, low or unclear risk of bias based on these factors. </p> <p>We used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) criteria to assess the overall quality of evidence used for specific outcomes in this review. Evidence from randomized controlled trials begin as high quality evidence. They can then be downgraded due to: (1) risk of bias from the studies, (2) indirect evidence, (3) inconsistency (unexplained heterogeneity), (4) imprecision in data, and (5) publication bias. The overall quality of evidence for each outcome was determined and classified as high quality (i.e. further research is very unlikely to change our confidence in the estimate of effect); moderate quality (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low quality (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); and very low quality (i.e. we are very uncertain about the estimate) (<a href="./references#CD007571-bbs2-0017" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>, <a href="./references#CD007571-bbs2-0025" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> <p>Disagreement among authors regarding risk of bias was resolved by consensus. In future updates of this review publication bias will be assessed by examining the authors and institutions involved, journal of publication, funding sources, and the affiliation of authors with manufacturers. </p> <p>Two authors (DJT and JKM) separately extracted data and results from relevant studies. The extracted data included patient demographics such as age, disease distribution, disease duration, and concomitant medications, the type of disease activity scoring instrument used, treatment and control modalities, the number of subjects randomized into each treatment group, the number of subjects maintaining remission and stopping steroids, the duration of treatment and follow up, and the number of subjects lost to follow up. The corresponding author was contacted in cases where data were not available from the published reports. </p> </section> <section id="CD007571-sec-0028"> <h4 class="title">Statistical analysis</h4> <p>Data were analyzed using Review Manager (RevMan 5.3). All data were analyzed on an intention‐to‐treat basis. The results were expressed as the risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes. The risk ratio was calculated using a fixed‐effect model. The definitions of clinical remission, clinical response, and endoscopic response were set by the authors of the included studies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007571-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007571-sec-0029"></div> <section id="CD007571-sec-0030"> <h3 class="title">Description of studies</h3> <p>The literature search conducted on 15 June 2014 identified 103 records. Six additional studies were identified through searching of conference abstracts. After duplicates were removed, a total of 82 studies remained for review of titles and abstracts. Two authors (DJT and JKM) independently reviewed the titles and abstracts of these trials and 32 studies were selected for full text review (see <a href="#CD007571-fig-0001">Figure 1</a>). Twelve reports of seven studies were excluded (See: <a href="./references#CD007571-sec-0047" title="">Characteristics of excluded studies</a>). Twenty reports of four studies met the pre‐defined inclusion criteria and were included in the review (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>; <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). </p> <div class="figure" id="CD007571-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007571-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p><a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a> was a safety and efficacy evaluation of vedolizumab. It was a randomized, double blind trial where 29 patients with moderately‐severe ulcerative colitis received a single dose of vedolizumab at various doses or a placebo and were followed for 30 days. One patient was excluded before randomization for not meeting inclusion criteria. The inclusion criteria included: a minimum score of five on the Mayo Clinic score, greater than or equal to three bowel movements per day and signs of active disease on endoscopy. Outcomes after 30 days were final Mayo Clinic scores, clinical remission (Mayo Clinic score of zero) and endoscopic response (two grade improvement in modified Baron score) (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>). </p> <p><a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>, enrolled 181 adult patients with active ulcerative colitis from 20 centers. The study duration was six weeks. Disease activity was quantified using the ulcerative colitis clinical score (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>), and the modified Baron score (<a href="./references#CD007571-bbs2-0013" title="BaronJH , ConnellAM , Lennard‐JonesJE . Variation between observers in describing mucosal appearances in proctocolitis. British Medical Journal1964;1(5375):89‐92. ">Baron 1964</a>). Active disease was defined as an ulcerative colitis clinical score of 5 to 9 points, with a score of at least 1 on either stool frequency or rectal bleeding, and a modified Baron score of at least 2 on sigmoidoscopic examination with active disease extending a minimum of 25 cm from the anal verge. Exclusion criteria included patients with current or recent topical therapy, corticosteroids, or immunosuppressives. A total of 181 patients were randomized to vedolizumab at doses of 0.5 mg/kg (n = 58) or 2 mg/kg (n = 60), or identical placebo (n = 63). Patients received study drug or placebo intravenously on day 1 and 29. The primary study outcome was the proportion of patients in clinical remission at week six, defined as an ulcerative colitis clinical score of zero or one and a modified Baron score of zero or one with no evidence of rectal bleeding. Secondary outcomes included the proportion of patients with a clinical response (defined as an improvement of three points or more on the ulcerative colitis clinical score), endoscopic remission and adverse events. Disease‐related quality of life was assessed by the inflammatory bowel disease questionnaire (IBDQ). </p> <p><a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> randomised 47 patients from 11 different centers. The study duration was 253 days. Patients received either vedolizumab at a dose of 2 mg/kg (n = 13), 6 mg/kg (n = 14) or 10 mg/kg (n = 11); or placebo (n = 9). Study medications were given on days 1, 15, 29 and 85. The primary goal of the study was to assess the clinical pharmacology and safety of a new formulation of vedolizumab, with efficacy (i.e. remission and response) being a secondary outcome. This new formulation was made with a substance produced in Chinese hamster ovary. Pharmacological evaluation included measuring serum vedolizumab concentrations and receptor saturation. Immunogenicity was evaluated by measuring the level of human antihuman antibodies. Evaluation of safety involved monitoring for any adverse events, with particular attention to PML. Contrary to <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>, this study did not involve endoscopic evaluation and used the partial Mayo score (<a href="./references#CD007571-bbs2-0021" title="LewisJD , ChuaiS , NesselL , LichtensteinGR , AberraFN , EllenbergJH . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflammatory Bowel Diseases2008;14(12):1660‐6. ">Lewis 2008</a>), as a measure of baseline disease state, remission and response. Remission was defined as a partial Mayo score of two or less with no subscore greater than one. Remission was only reported in a <i>post‐hoc</i> subgroup of patients with active disease (partial Mayo score of four to seven). Response was defined as a decrease of two or more and greater than 25% decrease in the partial Mayo score compared to baseline, along with a decrease in the rectal bleeding subscore of one or greater or an absolute subscore of zero or one for rectal bleeding. Endoscopic remission was not investigated in this study, however fecal calprotectin was used as a surrogate marker of intestinal inflammation (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). </p> <p><a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> randomised 374 patients to receive a 300 mg intravenous dose of vedolizumab (n = 225) or placebo (n = 149). The patients were then followed for 52 weeks. There were two phases to the trial: induction (weeks 1 to 6) and maintenance (weeks 7 to 52). The primary outcome was clinical response defined as a decrease in Mayo score by three or more and a 30% decrease from the baseline score and a decrease in the rectal bleeding subscore of one or greater or an absolute rectal bleeding subscore of one or less. Secondary outcomes included clinical remission (Mayo score of less than two and no subscale scores greater than one) and mucosal healing (Mayo endoscopic subscore of less than or equal to one) (<a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). </p> </section> <section id="CD007571-sec-0031"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment is summarized in <a href="#CD007571-fig-0002">Figure 2</a>. The studies were of high methodological quality. All four were randomised trials. The sequence generation technique was computer‐generated in all four studies. All four studies utilized a centralized randomization technique and were rated as low risk of bias for allocation concealment. All four studies were double‐blind, and used identical placebo and were rated as low risk of bias for blinding. All four studies used adequate methods to deal with missing data and were rated as low risk for incomplete outcome data. All of the studies reported results for all <i>a priori</i> outcomes and were rated as low risk for selective reporting. All four studies were rated as low risk for other sources of bias. </p> <div class="figure" id="CD007571-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007571-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD007571-sec-0032"> <h3 class="title" id="CD007571-sec-0032">Effects of interventions</h3> <p>See: <a href="./full#CD007571-tbl-0001"><b>Summary of findings for the main comparison</b> Vedolizumab versus placebo for induction of remission in ulcerative colitis</a> </p> <section id="CD007571-sec-0033"> <h4 class="title">Effectiveness of vedolizumab</h4> <p>A pooled analysis of four studies (n = 606 patients) showed a statistically significant difference in clinical remission rates favouring vedolizumab over placebo (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>; <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). After an induction phase of four to six weeks of therapy 77% (293/382) of vedolizumab patients failed to enter clinical remission compared to 92% (205/224) of placebo patients (RR 0.86, 95% CI 0.80 to 0.91). No significant heterogeneity was detected for this comparison (P = 0.57, I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence for the primary outcome (failure to achieve clinical remission) was high (See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>A pooled analysis of three studies (n = 601 patients) showed a statistically significant difference in clinical response rates favouring vedolizumab over placebo (<a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). After 6 weeks of treatment 48% (183/380) of vedolizumab patients failed to have a clinical response compared to 72% (159/221) of placebo patients (RR 0.68, 95% CI 0.59 to 0.78). No significant heterogeneity was detected for this comparison (P = 0.64, I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to sparse data (342 events, See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The pooled analysis examining endoscopic remission included three studies and 583 patients. It showed a statistically significant difference in endoscopic remission rates favouring vedolizumab over placebo (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>; <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). Sixty‐eight per cent (246/363) of vedolizumab patients failed to achieve endoscopic remission compared to 81% (178/220) of placebo patients (RR 0.82, 95% CI 0.75 to 0.91). No significant heterogeneity was detected for this comparison (P = 0.27, I<sup>2</sup> = 24%). A GRADE analysis indicated that the overall quality of the evidence for this outcome was high (See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). <a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a> (n = 28 patients) reported endoscopic response as an outcome. No statistically significant difference in failure to achieve endoscopic response was found between vedolizumab and placebo patients. In both groups 75% of patients failed to have an endoscopic response (RR 1.00; 95% CI 0.62 to 1.61). </p> <p><a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> reported significantly higher IBDQ scores in patients receiving vedolizumab compared to placebo. The mean IBDQ score was 171.5 in the vedolizumab group compared to 162.5 in placebo patients (P = 0.03). </p> <p><a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> reported on clinical and endoscopic relapse at 52 weeks (n = 373 patients) as outcomes. There was a statistically significant difference in clinical relapse rates favouring vedolizumab over placebo. Fifty‐seven per cent (140/247) of vedolizumab patients relapsed by 52 weeks follow‐up compared to 84% (106/126) of placebo patients (RR 0.67, 95% CI 0.59 to 0.77). A GRADE analysis indicated that the overall quality of the evidence for the primary outcome (clinical relapse) was moderate due to sparse data (246 events, See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). There was a statistically significant difference in endoscopic relapse rates favouring vedolizumab over placebo. Forty‐six per cent (114/247) of vedolizumab patients relapsed endoscopically by 52 weeks follow‐up compared to 80% (101/126) of placebo patients (RR 0.58, 95% CI 0.49 to 0.68). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to sparse data (215 events, See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Two studies evaluated the development of clinically relevant titers of human antihuman antibodies in study patients, which is associated with a decrease in the efficacy of vedolizumab (<a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> reported that 44% (52/188) of vedolizumab patients developed detectable human antihuman antibodies at week 8, compared to 11% (4/37) of vedolizumab patients in the <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> study. Furthermore, <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> reported that 24% (28/118) of patients with high antibody titers (greater than 1:125) had a remission rate similar to placebo patients (12% versus 14% respectively). In these patients the alpha4beta7 binding site was observed to be unsaturated on CD4+CD45RO+ T cells, which could have affected the efficacy of vedolizumab. One of the primary differences between the vedolizumab formulations used in <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> and <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> was the cell line used to produce the antibody. <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> used a NS0 mouse myeloma cell line, whereas <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> used a Chinese hamster ovary (CHO) cell‐based system. <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> used this CHO cell‐derived vedolizumab in an attempt to reduce the level of human antihuman antibodies. Comparing the two studies, it would appear that patients who received NSO mouse myeloma cell‐derived vedolizumab had a significantly higher chance of developing human antihuman antibodies compared to patients who received CHO‐cell derived vedolizumab (RR 4.08, 95% CI 1.58 to 10.51). </p> <p>Pooled data from <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> and <a href="./references#CD007571-bbs2-0024" title="SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a> (both ulcerative colitis and Crohn's patients) indicates that concomitant immunosuppressive therapy was associated with decreased immunogenicity in patients who were randomized to placebo for maintenance therapy. Human antihuman antibodies were detected in 3% (1/32) of patients who received concomitant immunosuppressive therapy compared to 18% (44/247) of patients who did not. </p> </section> <section id="CD007571-sec-0034"> <h4 class="title">Adverse Events</h4> <p>Adverse events occurred in similar numbers of patients treated with vedolizumab and placebo. Two studies reported the proportion of patients who experienced at least one adverse event (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> collected safety data up to day 253. Safety data from the <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study included the full safety population for both the induction (6 weeks) and maintenance phases (52 weeks, n = 895). A pooled analysis (n = 941 patients) found no statistically significant difference in the incidence of adverse events between vedolizumab and placebo patients. Seventy‐nine per cent (520/657) of vedolizumab patients experienced at least one adverse event compared to 80% (227/284) of placebo patients (RR 0.99, 95% CI 0.93 to 1.07). A GRADE analysis for this outcome showed the overall quality of evidence was high (See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Two of the studies reported on withdrawals due to adverse events as an outcome (<a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> reported that no patients withdrew due to adverse events. A pooled analysis (2 studies, 941 patients) showed that significantly fewer vedolizumab patients withdrew due to adverse events compared to placebo patients. Six per cent of vedolizumab patients withdrew due to adverse events compared to 11% of placebo patients (RR 0.55, 95% CI 0.35 to 0.87). </p> <p>A pooled analysis of three studies (<a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>), including 1122 patients showed that the likelihood of serious adverse events was not significantly increased by the administration of vedolizumab. Twelve per cent (97/775) of vedolizumab patients had a serious adverse event compared to 12% (43/347) of placebo patients (RR 1.02, 95% CI 0.73 to 1.42). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to sparse data (136 events, See <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>). Serious adverse events reported in the <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> study included exacerbation of colitis, angioedema with an infusion reaction, infection and degenerative disk disease. <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> reported two serious adverse events in the vedolizumab group including compression fractures of the thoracic vertebrae in one patient and gastroduodenitis in another patient. </p> <p>The most commonly reported adverse event in the <a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a> study was headache. Commonly reported adverse events in the <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> study included: worsening ulcerative colitis, nausea, headache, frequent bowel movements, fatigue, nasopharyngitis and abdominal pain. In the <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> study three notable adverse events occurred in the setting of vedolizumab administration: one patient developed an infusion reaction with hives and angioedema, one patient developed a primary CMV infection, and one patient developed postoperative pneumonia after spine surgery. The patient that developed the infusion reaction had high anti‐vedolizumab antibody titers (1:3125). Commonly reported adverse events in the <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> study included: headache, worsening ulcerative colitis, upper respiratory tract infection and nasopharyngitis. <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> reported two incidents of pyrexia, but no allergic reactions to the medication. No systemic opportunistic infections or neoplasms were reported (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). Commonly reported adverse events in the <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study included: worsening ulcerative colitis, headache, nasopharyngitis, arthralgia, upper respiratory tract infection, nausea, cough, anemia, abdominal pain, fatigue and influenza. There were no reports of PML in any of the four studies (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>; <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). This is substantial finding as this has been observed in other biologic therapies against integrins (e.g. natalizumab) (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007571-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007571-sec-0035"></div> <p>The results of this meta‐analysis show that vedolizumab is significantly superior to placebo for induction of clinical remission, clinical improvement, and endoscopic remission and prevention of clinical relapse and endoscopic relapse in ulcerative colitis. Although vedolizumab did not appear to have any significant effect on endoscopic response (RR 1.00, 95% CI 0.24 to 4.14), only one small inadequately powered study assessed this outcome (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>). Furthermore, vedolizumab was not significantly associated with an increased rate of adverse events or serious adverse events relative to placebo. Withdrawal due to adverse events was significantly more likely in placebo patients than vedolizumab patients. This may be due to higher rates of worsening ulcerative colitis in placebo treated patients. </p> <p>We believe that the methodological basis for these conclusions is sound. The Cochrane risk of bias tool was used to assess the quality of four included trials and the possibility of bias was judged to be low for these studies. Furthermore, the primary outcome failure to induce clinical remission was rated as 'high' using the GRADE criteria indicating that further research is unlikely to change our confidence in the point estimate of effect. The primary outcome relapse was rated as 'moderate' using the GRADE criteria indicating that further research may change the point estimate of effect. The adverse event outcomes data (any adverse event and serious adverse events) were rated as 'moderate'. Further evaluation, particularly long‐term data is necessary to elucidate the risk of adverse events associated with the use of vedolizumab. These findings are summarized in the <a href="./full#CD007571-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Future research should consider comparing vedolizumab to other active treatments (e.g. infliximab or natalizumab), as it is difficult to choose between two therapies without a direct comparison of efficacy and adverse events. There have been indirectly observed benefits of vedolizumab over previous less selective alpha4 integrin blockers (e.g. natalizumab). Natalizumab has been associated with the development of PML, a rare infection of the brain caused by reactivated JC virus (<a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a>). PML is normally seen in immunocompromised patients (<a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a>). <a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a> investigated the risk of PML among patients receiving natalizumab and reported a total of 212 cases of PML among 99,571 patients receiving natalizumab (2.1 cases per 1000 patients). Forty‐six of these patients (22%) died. <a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a> identified three risk factors for the development of PML: prior use of immunosuppressants, increased length of therapy (especially beyond two years), and presence of anti‐JC virus antibodies. It is important to note that of the identified cases who had samples available for analysis for these antibodies (n = 54), all of the patients tested positive for anti‐JC virus antibodies. Risk stratification by these factors is applicable for treating patients with natalizumab, as outlined by <a href="./references#CD007571-bbs2-0014" title="BloomgrenG , RichmanS , HotermansC , SubramanyamM , GoelzS , NatarajanA , et al. Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. New England Journal of Medicine2012;366(20):1870‐80. ">Bloomgren 2012</a>, and may prove to be helpful in vedolizumab if any cases of PML are identified in vedolizumab treated patients. </p> <p>Vedolizumab is more selective than previous generations of integrin antagonists, blocking alpha4beta7 integrin specifically. Alpha4beta7 integrin is found on T and B cells and binds to mucosal addressin cell adhesion molecule‐1 (MAd‐CAM‐1) which is expressed primarily on the vascular endothelial cells of the intestines (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). Concerns over the potential for vedolizumab‐associated PML prompted <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> to have a special protocol for any patients displaying symptoms of PML. However, there were no reported cases of PML in any of the studies included in this review (<a href="./references#CD007571-bbs2-0001" title="FeaganB , McDonaldJWD , GreenbergG , WildG , PareP , FedorakRN , et al. An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A874. ">Feagan 2000</a>; <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>; <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>; <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a>). Vedolizumab likely has little or no risk of PML as a result of its selectivity, as lymphocyte trafficking to the central nervous system is not impaired. At present testing for anti‐JC virus antibodies in patients receiving vedolizumab does not appear to be helpful. </p> <p>The development of human antihuman antibodies has been reported in patients treated with vedolizumab. Human antihuman antibodies can interfere with drug efficacy. For example, <a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a> reported that 24% of patients had high titers of human antihuman antibodies (&gt;1:125) and these patients had a clinical remission rate similar to the placebo group. Forty‐four per cent of patients who received vedolizumab in this study developed detectable human antihuman antibodies (<a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>). One way of addressing this issue was to change the formulation of vedolizumab from a NS0 mouse myeloma cell line (<a href="./references#CD007571-bbs2-0002" title="FeaganBG , GreenbergG , WildG , McDonaldJW , FedorakR , PareP , et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD). Gastroenterology2003;124(4 Suppl 1):A25‐6. FeaganBG , GreenbergGR , WildG , FedorakRN , ParéP , McDonaldJW , et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine2005;352(24):2499‐507. ">Feagan 2005</a>), to a Chinese hamster ovary (CHO) cell system (<a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a>). <a href="./references#CD007571-bbs2-0004" title="ParikhA , LeachT , WyantT , ScholzC , SankohS , MouldDR , et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study. Inflammatory Bowel Diseases2012;18(8):1470‐9. ">Parikh 2012</a> reported the development of human antihuman antibodies in only 11% of patients who received CHO cell‐derived vedolizumab. We compared the two formulations and it appears that patients who received NSO mouse myeloma cell‐derived vedolizumab had a significantly higher chance of developing human antihuman antibodies compared to patients who received CHO‐cell derived vedolizumab (RR 4.08, 95% CI 1.58 to 10.51). Thus the CHO cell‐derived vedolizumab may be more effective than the NSO formulation. The <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study used a CHO‐cell derived formulation of vedolizumab. Pooled data from the <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> and <a href="./references#CD007571-bbs2-0024" title="SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a> studies (both ulcerative colitis and Crohn's patients) suggests that combination therapy with an immunosuppressive may prevent the formation of human antihuman antibodies. However, this result needs to be confirmed by future research. </p> <p>In conclusion, vedolizumab has been shown to be significantly more efficacious than placebo. Furthermore, the current CHO cell‐derived version of vedolizumab appears to have a lower incidence of human antihuman antibodies, which should be more efficacious than the previous NS0 cell‐derived version. To date, no cases of PML have been reported in vedolizumab treated patients and the incidence of other adverse events was not statistically different between vedolizumab and placebo. The results of the GRADE analysis indicate that overall quality of the evidence supporting the efficacy and safety of vedolizumab for treatment of active and quiescent ulcerative colitis is moderate to high. Future studies should compare vedolizumab to other active therapies for induction and maintenance of remission in ulcerative colitis. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD007571-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007571-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007571-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 1 Failure to induce clinical remission." data-id="CD007571-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 1 Failure to induce clinical remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 2 Failure to induce clinical response." data-id="CD007571-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 2 Failure to induce clinical response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 3 Failure to induce endoscopic remission." data-id="CD007571-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 3 Failure to induce endoscopic remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 4 Failure to induce endoscopic response." data-id="CD007571-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 4 Failure to induce endoscopic response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 5 Clinical relapse at 52 weeks." data-id="CD007571-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 5 Clinical relapse at 52 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 6 Endoscopic relapse at 52 weeks." data-id="CD007571-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 6 Endoscopic relapse at 52 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 7 Adverse Events." data-id="CD007571-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 7 Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 8 Withdrawal due to adverse events." data-id="CD007571-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 8 Withdrawal due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007571-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/urn:x-wiley:14651858:media:CD007571:CD007571-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_t/tCD007571-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vedolizumab versus placebo, Outcome 9 Serious Adverse Events." data-id="CD007571-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Vedolizumab versus placebo, Outcome 9 Serious Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/media/CDSR/CD007571/image_n/nCD007571-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007571-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vedolizumab versus placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Vedolizumab versus placebo for induction of remission in ulcerative colitis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with moderately to severely active ulcerative colitis<br/> <b>Settings:</b> Outpatients<br/> <b>Intervention:</b> Vedolizumab versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vedolizumab versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>915 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>787 per 1000</b> <br/> (732 to 833) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.80 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>720 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>490 per 1000</b> <br/> (425 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b> <br/> (0.59 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>601<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>809 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>663 per 1000</b> <br/> (607 to 736) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b> <br/> (0.75 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>841 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>563 per 1000</b> <br/> (496 to 648) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b> <br/> (0.59 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>802 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>465 per 1000</b> <br/> (393 to 545) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b> <br/> (0.49 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>799 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>791 per 1000</b> <br/> (743 to 855) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> <br/> (0.93 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>941<br/> (2 studies)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>121 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>122 per 1000</b> <br/> (87 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.72 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1122<br/> (3 studies)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Sparse data (342 events).<br/> <sup>3</sup> Sparse data (246 events).<br/> <sup>4</sup> Sparse data (215 events).<br/> <sup>5</sup> Includes full safety population from <a href="./references#CD007571-bbs2-0003" title="FeaganB , ColombelJF , RubinD , ModyR , SankohS , LaschK . Improvements in health‐related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn's and Colitis2014;8:S51‐2. FeaganB , RutgeertsP , SandsB , SandbornW , ColombelJF , HanauerS . Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. American Journal of Gastroenterology2012;107:S609‐10. FeaganB , SandbornWJ , SmythM , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn's and Colitis2014;8:S276‐7. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo‐controlled, double‐blind, multi‐centre trial. Journal of Crohn's and Colitis2013;7:S216. FeaganB , SandsB , SankohS , MilchC , FoxI . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1‐2. FeaganBG , ColombelJF , RubinDT , ModyR , SankohS , LaschK . Health‐related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study. Gastroenterology2014;146(5 Suppl 1):S590. FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. FeaganBG , RutgeertsPJ , SandsBE , ColombelJ , SandbornWJ , HanauerSB , et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter phase 3 trial. Gastroenterology2012;142(5 Suppl 1):S160‐1. FeaganBG , SandbornW , SmythMD , SankohS , ParikhA , FoxI . Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Gastroenterology2014;146(5 Suppl 1):S590. ParikhA . Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S26. RosarioM , FoxI , MilchC , ParikhA , FeaganB , SandbornW , et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2. Inflammatory Bowel Diseases2013;19:S80. RosarioM , FrenchJ , DirksN , MiltonA , FoxI , GastonguayM . Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis. Journal of Crohn's and Colitis2014;8:S270‐1. RosarioM , WyantT , MilchC , ParikhA , FeaganB , SandbornWJ , et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. Journal of Crohn's and Colitis2014;8:S42‐3. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo‐controlled, double‐blind, multicenter trial. Journal of Crohn's and Colitis2013;7:S138‐9. SandbornW , SandsB , RutgeertsP , SankohS , RosarioM , MilchC , et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in gemini i, a randomized, placebo‐controlled, double‐blind, multicenter trial. Inflammatory Bowel Diseases2012;18:S1. SandsB , HanauerS , ColombelJF , DaneseS , AbreuM , AhujaV , et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. American Journal of Gastroenterology2013;108:S503. ">Feagan 2013</a> study (induction and maintenance phase).<br/> <sup>6</sup> Sparse data (136 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vedolizumab versus placebo for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/full#CD007571-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007571-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vedolizumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to induce clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.80, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure to induce clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.59, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to induce endoscopic remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.75, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure to induce endoscopic response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.62, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical relapse at 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.59, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Endoscopic relapse at 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.49, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vedolizumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007571.pub2/references#CD007571-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007571.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007571-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007571-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007571-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007571\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007571\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007571\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007571\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007571\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007571.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007571.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007571.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007571.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007571.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727019124"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007571.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727019128"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007571.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea1d3ede9f401',t:'MTc0MDcyNzAxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 